The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells

doi:10.4049/jimmunol.0801279

J Immunol. Author manuscript; available in PMC 2010 November 22.

Published in final edited form as:

J Immunol. 2009 April 15; 182(8): 4616–4623.

doi: 10.4049/jimmunol.0801279

PMCID: PMC2989878

NIHMSID: NIHMS242452

The A_2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells¹

Jeffrey M. Wilson,^* William G. Ross,^* Oma N. Agbai,^* Renea Frazier,^† Robert A. Figler,^† Jayson Rieger,^† Joel Linden,^* and Peter B. Ernst^*²

^* Department of Medicine, University of Virginia, Charlottesville, VA 22908

^† Adenosine Therapeutics Group, PGxHealth, a Division of Clinical Data, Charlottesville, VA 22908

² Address correspondence and reprint requests to Dr. Peter B. Ernst, University of Virginia, Department of Medicine, P.O. Box 100708, Charlottesville, VA 22908. Email: pernst/at/virginia.edu

The publisher's final edited version of this article is available free at J Immunol

See other articles in PMC that cite the published article.

Abstract

The endogenous purine nucleoside adenosine is an important antiinflammatory mediator that contributes to the control of CD4⁺ T cell responses. While adenosine clearly has direct effects on CD4⁺ T cells, it remains to be determined whether actions on APC such as dendritic cells (DC) are also important. In this report we characterize DC maturation and function in BMDC stimulated with LPS in the presence or absence of the nonselective adenosine receptor agonist NECA (5′-N-ethylcarboxamidoadenosine). We found that NECA inhibited TNF-α and IL-12 in a concentration-dependent manner, whereas IL-10 production was increased. NECA-treated BMDC also expressed reduced levels of MHC class II and CD86 and were less effective at stimulating CD4⁺ T cell proliferation and IL-2 production compared with BMDC exposed to vehicle control. Based on real-time RT-PCR, the A_2A adenosine receptor (A_2AAR) and A_2BAR were the predominant adenosine receptors expressed in BMDC. Using adenosine receptor subtype selective antagonists and BMDC derived from A_2AAR^−/− and A_2BAR^−/− mice, it was shown that NECA modulates TNF-α, IL-12, IL-10, and CD86 responses predominantly via A_2BAR. These data indicate that engagement of A_2BAR modifies murine BMDC maturation and suggest that adenosine regulates CD4⁺ T cell responses by selecting for DC with impaired immunogencity.

Adenosine is an endogenous purine nucleoside that exerts myriad antiinflammatory activities on host cells via signaling through the G protein-coupled P1 purinergic receptors (1). Postulated to act in an autoinhibitory fashion to restrain local inflammation, adenosine accumulates at hypoxic or inflammatory sites and binds to adenosine receptors that are up-regulated on cells following activation (1–3). Of the four characterized P1 receptors, which include the A₁ adenosine receptor (A₁AR)³, A_2AAR, A_2BAR, and A₃AR, the G_s-coupled A_2AAR has been regarded to mediate most antiinflammatory responses (4, 5) However, other adenosine receptors may also be important inflammatory regulators (6–10).

Adenosine analogs have proven to be protective in a number of inflammatory disease models, including ischemia-reperfusion, colitis, autoimmune pneumonitis, and type I diabetes (11–15). Actions on CD4⁺ T cells are suggested to underlie many of the beneficial effects described in these models (11, 12, 16, 17). Cytokine production, expression of activation markers, and proliferation are impaired by direct engagement of A_2AAR on stimulated CD4⁺ cells in vitro (11, 17, 18). In a T cell transfer model of colitis, both effector and regulatory T cells were shown to be defective when lacking A_2AAR (11). Furthermore, regulatory T cell-generated adenosine may suppress T effectors, as expression of CD39 and CD73 on regulatory T cells converts nucleotide precursors into adenosine (19–21). Finally, adenosine has been reported to promote peripheral tolerance by favoring the development of adaptive LAG-3⁺ regulatory T cells (12).

In addition to direct effects, adenosine may also indirectly modify CD4⁺ T cell responses via regulation of accessory cells such as dendritic cells (DC). DC are potent APC that play an important role in controlling the quantity and quality of immune responses through recognition of both foreign and host molecules (22–24). Previous studies have shown that adenosine receptors are expressed on human and murine DC and have been shown to have effects on cytokine production, migration, and costimulatory marker expression (25–29). The role of specific adenosine receptors in controlling DC, and in turn CD4⁺ T cell responses, is still unclear. The aim of this study was to characterize adenosine receptor expression and function in murine DC maturation using a combined genetic and pharmacologic approach. We found that the nonselective adenosine agonist 5′-N-ethylcarboximadoadenosine (NECA) modulates TNF-α, IL-12, and IL-10 production, as well as CD86 and MHC-II expression in BMDC stimulated with LPS, predominantly via A_2BAR. Moreover, as these BMDC did not efficiently support CD4⁺ T cell activation, these data suggest that adenosine impairs immunogenicity through actions on the DC.

Materials and Methods

Mice

C57BL/6, BALB/c, and OT-II mice were purchased from The Jackson Laboratory. A_2AAR^−/−, A_2BAR^−/− (kindly provided by Dr. K. Ravid), A₃AR^−/−, and A_2AAR^−/−/A_2BAR^−/− mice on a C57BL/6 background were bred and maintained at the University of Virginia (7, 17). All mice were housed and handled in accordance with the Institutional Animal Care and Use Committee of the University of Virginia.

Reagents

NECA was purchased from Sigma-Aldrich; 4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo[2,3-α][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) and 2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine (SCH58261) were purchased from Tocris Bioscience. A novel 1,3-dialkyl-8-hetero substituted xanthine (ATL692) was kindly provided by Adenosine Therapeutics. Anti-mouse CD11c-FITC (HL3), I-A/I-E-PE (M5/114.15.2), CD40-PE (3/23), CD80-PE (16-10A1), and CD86-PE (GL1) Abs were purchased from BD Biosciences. Anti-mouse IL-10 (JES5-16E3) and anti-TGFβ (MAB1835) were purchased from eBioscience and R&D Systems, respectively.

Generation of BMDC

Donor mice were euthanized and then bone marrow was flushed from femurs and tibias, RBC were lysed with ACK buffer, and cells were suspended to 1 × 10⁶/ml in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM 2-Me, 25 mM HEPES, 2 mM sodium pyruvate, and 20 ng/ml GM-CSF (PeproTech). Cells were cultured in T-75 flasks at 37°C/5% CO₂, and then fresh media was supplemented with GM-CSF added on day 3. In some experiments 3 ng/ml GM-CSF and 3 mg/ml IL-4 (PeproTech) were used in lieu of 20 ng/ml GM-CSF. After 6 days, nonadherent cells were harvested and enriched with CD11c MACS kit and LS columns (Miltenyi Biotec) according to the manufacturer’s instructions. Experiments with BMDC were conducted in complete media supplemented with 5 ng/ml GM-CSF.

Isolation of lamina propria DC

CD11c⁺-enriched cells from small intestine lamina propria were isolated as described previously (30). Briefly, small intestines were removed from euthanized donor C57BL/6 mice, opened longitudinally to flush out feces, cut into 15-mm pieces, and then incubated for 20 min at 37°C on a shaker in HBSS supplemented with 5% heat-inactivated FBS and 2 mM EDTA. After passing the preparation through a metal filter, intestinal fragments were collected and the step was repeated. Then, intestinal fragments were minced and incubated for 20 min at 37°C on a shaker in HBSS supplemented with 5% heat-inactivated FBS and 1 mg/ml type VIII collagenase (Sigma-Aldrich). The cell suspension was passed through a cell strainer to remove debris, washed once with complete BMDC media, and then CD11c⁺ cells were enriched with the CD11c MACS kit.

Cytokines

Supernatant was collected from BMDC treated in presence or absence of 500 ng/ml LPS (Escherichia coli O127:B8, phenol purified (31); Sigma-Aldrich) and NECA for 18 h. In some experiments cells were pretreated for 15 min with the adenosine receptor selective antagonists ZM241385, SCH58261, or ATL692. TNF-α, IL-12p70, and IL-10 protein were measured using ELISA kits (BD Pharmingen).

Flow cytometry

BMDC were treated in presence or absence of LPS and NECA for 24 h and nonadherent/semiadherent cells were harvested by washing twice with PBS. BMDC were then resuspended into PBS/2% FBS, stained with FITC-or PE-conjugated Abs on ice for 30 min, washed twice with PBS/2% FBS, and fixed in PBS/2% paraformaldehyde. Samples were assayed with a FACSCalibur flow cytometer and data were analyzed with CellQuest (BD Biosciences) and FlowJo (Tree Star) software. For some coculture experiments, BMDC treated with NECA and LPS for 16 h were harvested and stained with anti-CD86 Ab. CD86^low and CD86^high BMDC were sorted using a FACSVantage cell sorter (BD Biosciences).

Real-time RT-PCR

BMDC were lysed and total RNA was isolated with Qiagen Miniprep kits and then reverse transcribed into cDNA with SuperScript II (Invitrogen) according to the manufacturer’s recommendations. Adenosine receptor and cytokine transcripts were measured by real-time RT-PCR with primer and dual-labeled probes (Applied Biosystems) detected in a SmartCycler (Cepheid) and normalized against 18S rRNA. The fold change in expression of a given gene of interest was determined using the ΔΔC_T method (32). The ability of all primers and dual-labeled probes to detect transcripts using mRNA from the appropriate positive control tissue or cell line was confirmed.

cAMP

BMDC were treated with 1 μM rolipram (Sigma-Aldrich) in presence or absence of 250 nM NECA for 15 min and then lysed with 0.1M HCl/0.1% Triton X-100. In some experiments cells were pretreated overnight with 500 ng/ml LPS. Lysate was stored at −70°C until assayed by cAMP kit (Assay Designs) according to the manufacturer’s instructions.

Cocultures

BMDC from different treatment groups, including in some cases BMDC sorted into CD86^low and CD86^high populations, were added to wells of 96-well plates in graded concentrations. For proliferation experiments BMDC were irradiated with 3000 rad before addition to cocultures. CD4⁺ T cells were isolated from OT-II, C57BL/6, or BALB/c splenocytes by positive selection using CD4 MACS bead enrichment (Miltenyi Biotec) and 1 × 10⁵ CD4⁺ T cells were added to the cultures. For cocultures with OT-II CD4⁺ T cells, BMDC were first pulsed overnight with 5 μg/ml OVA and then washed. For polyclonal syngeneic cocultures, 500 ng/ml soluble anti-CD3 Ab (145-2C11; BD Biosciences) was added. Cell proliferation was assessed after 72–96 h by measuring the incorporation of [³H]thymidine (MP Biomedicals) added during the last 16 h of culture using a TriLux liquid scintillation counter (Perkin-Elmer). Supernatant was collected after 24 – 48 h and IL-2 was assayed by ELISA kit (BD Biosciences).

Radioligand binding assays

Our binding methodology has been described previously (33). In brief, all four subtypes of recombinant murine adenosine receptors were stably expressed in HEK293 cells (A_2AAR, A_2BAR, and A₃AR) or CHO-K1 cells (A₁AR). Crude membrane preparations from these transfected cells were diluted in HE buffer (50 mM HEPES, 1 mM EDTA (pH 7.4)) at concentrations between 2 and 35 μg/tube in a volume of 150 μl. Dilutions of antagonist compounds were prepared in HE plus adenosine deaminase (2 U/ml), MgCl₂ (10 mM), and an appropriate radioligand (¹²⁵I-ABA for A₁AR and A₃AR, ¹²⁵I-ZM241385 for A_2AAR, and ¹²⁵I-ABOPX for A_2BAR). Diluted antagonists (25 μl) were added to each membrane sample (150 μl), and the tubes were incubated for 2 h at room temperature and then filtered through glass-fiber filters and counted. Samples were assayed in triplicate. Nonspecific binding was measured in the presence of NECA (100 μM).

Statistical analysis

Percentage maximal cytokine production was determined by: % Max = 100 – [(vehicle control treated with LPS – untreated) – (NECA with LPS – untreated)]/(vehicle control treated with LPS – untreated) × 100. Data are reported as means ± SEM. The two-tailed Student’s t test assuming unequal variance was performed using Microsoft Excel software. A p value of <0.05 was considered significant and is denoted by an asterisk.

Results

LPS-induced maturation of BMDC is modulated by an adenosine analog

The stable, nonselective adenosine analog NECA was used to determine the role of adenosine receptors in regulating DC maturation and function in response to an inflammatory stimulus. BMDC were stimulated with LPS in the presence of NECA or DMSO vehicle control and assessed for cytokine production, costimulatory marker, and MHC-II expression, as well as the capacity to promote CD4⁺ T cell activation. Because previous studies have shown that TNF-α, IL-12, and IL-10 expression are regulated by adenosine receptors in some APC (26, 34), we determined whether these cytokines are modulated in murine BMDC. We found that NECA significantly inhibited TNF-α and IL-12 in a concentration-dependent manner, whereas the antiinflammatory cytokine IL-10 was increased (Fig. 1A). IL-10 was further investigated by real-time RT-PCR and found to be rapidly up-regulated by NECA (Fig. 2A). In the absence of inflammatory stimulus, NECA had little effect on cytokine production. As MHC-II and costimulatory molecules are important in CD4⁺ T cell activation by DC, we characterized the effect of NECA on BMDC expression of MHC-II, CD40, CD80, and CD86. NECA significantly impaired expression of MHC-II and CD86 in LPS-stimulated BMDC as compared with vehicle control, but had little effect on CD40 or CD80 (Fig. 1B and Table I). Interestingly, the MHC-II and CD86 inhibition was consistently observed in a subset of BMDC but not in the entire population. As an additional measure of DC maturation and function, LPS-stimulated BMDC were treated with NECA or vehicle control for 18 h and then washed thoroughly and cocultured with CD4⁺ T cells. An OVA_323–339-specific coculture with CD4⁺ T cells derived from OT-II mice, as well as a one-way MLR with C57BL/6 BMDC and BALB/c CD4⁺ T cells, was employed. After 24 – 48 h supernatant was collected and assayed for IL-2 as a measure of T cell activation. Significantly less IL-2 was produced with NECA-treated BMDC in both the OVA_323–339-specific coculture and the one-way MLR, as compared with vehicle control-treated BMDC (Fig. 1C). To determine the role that antiinflammatory molecules such as IL-10 or TGFβ may play in mediating the observed effects of NECA, studies were conducted using neutralizing Abs. NECA impairment of IL-12 and CD86, but not TNF-α, was largely reversed by a neutralizing IL-10 Ab (Fig. 2, B and C). In contrast, a neutralizing Ab to TGFβ had little effect (data not shown).

FIGURE 1

The nonselective adenosine analog NECA modulates LPS-induced BMDC maturation. A, MACS CD11c⁺ BMDC were treated with 1 μM NECA or DMSO vehicle control in the presence or absence of 500 ng/ml LPS, and after 18 h supernatant was collected. TNF-α (more ...)

FIGURE 2

IL-10 is an important mediator in the regulation of BMDC by NECA. A, BMDC were treated in presence or absence of LPS and 250 nM NECA. At various time points, cells were lysed, RNA was isolated, and real-time RT-PCR was conducted to determine IL-10 mRNA (more ...)

Table I

MHC-II, CD40, CD80, and CD86 expression on BMDC: cells treated with NECA and LPS are compared to relevant controls^a

Adenosine receptor expression in DC

To determine which adenosine receptors modulate BMDC maturation, we first determined which receptors were expressed in BMDC using real-time RT-PCR. A_2AAR, A_2BAR, and A₃AR, but not A₁AR, transcripts were detected to varying degrees in resting BMDC (Fig. 3A), with A_2BAR being the predominant transcript in resting cells. Since previous studies have shown that A_2AAR is substantially up-regulated in other immune cells in response to activation, we characterized adenosine receptor transcripts in LPS-stimulated BMDC (2, 17). As shown in Fig. 3B, A_2AAR transcripts were significantly induced in BMDC, peaking at 3 h poststimulation with a 10.1-fold increase over resting levels. A_2BAR transcripts increased less dramatically, showing a significant elevation of 2.9-fold at 1 h and then returning to baseline. In contrast to A_2AAR and A_2BAR, A₃AR levels decreased upon LPS stimulation and the A₁AR transcript was still not detected. Accumulation of intracellular cAMP can be used as a measure of functional A_2AAR and A_2BAR activity because both receptors are G_s-coupled. Thus, to validate that adenosine receptor mRNA correlates with the expression of functional receptors, cAMP assays were conducted. As shown in Fig. 3C, BMDC treated with NECA had significantly elevated cAMP levels as compared with vehicle control-treated cells. Moreover, BMDC that had been stimulated overnight with LPS produced significantly more cAMP than did resting cells in response to NECA. To further characterize adenosine receptor expression in an important in vivo DC population, we enriched for CD11c⁺ cells from small intestine lamina propria. Although these cells expressed a different adenosine receptor profile than our BMDC, A_2BAR was still expressed at relatively high levels (Fig. 3D).

FIGURE 3

DC expression of adenosine receptors as measured by real-time RT-PCR and cAMP functional studies. A, Adenosine receptor mRNA in resting BMDC. Data represent the mean ± SEM from 10 or more experiments B, Kinetics of adenosine receptor mRNA expression (more ...)

NECA impairment of BMDC maturation requires the A_2B adenosine receptor

Having determined that A_2AAR and A_2BAR are the predominant adenosine receptors expressed in BMDC, additional experiments were conducted to define the relative contribution of these receptors in modulating BMDC maturation. Responses to NECA were compared in BMDC from wild-type mice or from mice deficient for various adenosine receptors. As a complementary approach, adenosine receptor antagonists selective for A_2AAR and/or A_2BAR (Table II) were also used. NECA modulation of TNF-α, IL-12, and IL-10 was significantly ablated in A_2BAR^−/− as compared with wild-type BMDC (Fig. 4A). In contrast, cytokine production in A_2AAR^−/− BMDC treated with NECA differed little from wild-type cells. Importantly, neither baseline nor LPS-induced cytokine levels differed substantially between wild-type and knockout mice (supplemental Table I).⁴ To further probe adenosine receptor regulation of cytokine responses, experiments were conducted with BMDC deficient for A₃AR or both A_2AAR and A_2BAR. Whereas NECA modulated A₃AR^−/− BMDC comparable to wild-type, it had essentially no effect on A_2AAR^−/−/A_2BAR^−/− BMDC (supplemental Fig. 1). Preincubation of wild-type BMDC with the mixed A_2AAR/A_2BAR antagonist ZM241385 or the A_2BAR selective antagonist ATL692 right-shifted NECA dose-response curves (Fig. 4B), whereas the A_2AAR selective antagonist SCH58261 had a less substantial effect. Taken together, both genetic and pharmacologic approaches suggest that NECA modulation of TNF-α, IL-12, and IL-10 in LPS-stimulated BMDC is mediated predominantly by activation of the A_2BAR, with a small contribution from A_2AAR. Because a recent study using BMDC generated with both GM-CSF and IL-4 implicated A₁AR in regulating DC maturation (29), we also assessed the expression and function of A_2BAR in BMDC cultivated with 3 ng/ml GM-CSF and 3 ng/ml IL-4. BMDC prepared in this manner still did not express A₁AR and expressed comparable levels of A_2BAR and A₃AR. Interestingly, A_2AAR was elevated ~5-fold in BMDC cultivated with both GM-CSF and IL-4 as compared with GM-CSF alone (supplemental Fig. 2A). Using the pharmacologic approach it was determined that A_2AAR plays a more substantial role in regulating LPS-induced cytokine responses in these cells; however, A_2BAR is still important (supplemental Fig. 2B).

Table II

Antagonist binding affinities for mouse adenosine receptors^a

FIGURE 4

NECA modulates LPS-induced TNF-α, IL-12, and IL-10 in an A_2BAR-dependent manner. BMDC were treated with LPS in the presence or absence of varying concentrations of NECA. Supernatants were collected after 18 h and cytokines were measured by ELISA. (more ...)

The relative contribution of A_2AAR and A_2BAR in mediating NECA inhibition of CD86 was also investigated. Whereas NECA impaired CD86 expression in wild-type and A_2AAR^−/− BMDC, this impairment was largely lost in A_2BAR^−/− BMDC (Fig. 5A and supplemental Fig. 3A). Similar experiments were also conducted with BMDC lacking A₃AR or both A_2AAR and A_2BAR. NECA inhibited CD86 in A₃AR^−/− BMDC comparable to wild-type, whereas the effect was completely abolished in the A_2AAR^−/−/A_2BAR^−/− BMDC (Fig. 5A and supplemental Fig. 1B). Preincubation of wild-type BMDC with the mixed A_2AAR/A_2BAR antagonist ZM241385 blocked NECA impairment of CD86, confirming that NECA acts through some combination of A_2AAR and A_2BAR to achieve its effect. The A_2AAR selective antagonist SCH58261 had little effect on the NECA response, whereas the A_2BAR selective antagonist ATL692 largely deterred NECA actions on CD86 (Fig. 5B and supplemental Fig. 3B). Collectively, these data suggest that NECA impairment of CD86 is mediated predominantly through A_2BAR, and they can be accounted for entirely by the combined effects of A_2AAR and A_2BAR.

FIGURE 5

NECA inhibits LPS-induced CD86 expression in an A_2BAR-dependent manner. BMDC were treated with LPS in the presence or absence of 250 nM NECA. Cells were harvested after 24 h, stained with anti-CD86-PE or isotype control, and assayed by flow cytometry. (more ...)

NECA-treated CD86^low BMDC do not support CD4⁺ T cell activation

NECA clearly impairs CD86 expression in LPS-stimulated BMDC (Fig. 1B and Table I); however, in all experiments conducted this response was incomplete and a subset of BMDC maintained elevated CD86 expression. This was the case even when higher concentrations of NECA were used, indicating that it is not simply a dose effect (data not shown). We sought to determine whether the NECA-responsive and nonresponsive populations differed in their expression of adenosine receptors and whether they had different functional capacities. BMDC stimulated with LPS in the presence of NECA for 16 h were harvested, stained with anti-CD86 Ab, and then sorted into CD86^low and CD86^high subsets (Fig. 6A). The CD86^low population expressed 2.6 ± 0.2-fold more A_2BAR mRNA than did the CD86^high population, whereas for A_2AAR the opposite was observed and CD86^low cells expressed 3.6 ± 0.8-fold less than did CD86^high cells (Fig. 6B).

FIGURE 6

NECA-treated CD86^low BMDC express more A_2BAR and altered cytokine response as compared with NECA-treated CD86^high or vehicle control-treated BMDC. NECA-treated, LPS-stimulated BMDC were harvested after 16 h and sorted into CD86^low and CD86^high populations. (more ...)

Expression of TNF-α, IL-12p40, and IL-10 mRNA was also evaluated in the NECA-treated CD86^low and CD86^high populations, as well as unsorted control populations (Fig. 6C). Compared with unsorted BMDC treated with vehicle control, both the CD86^low and CD86^high NECA-treated populations had significantly reduced TNF-α mRNA. IL-12p40 mRNA was significantly reduced in NECA-treated CD86^low cells as compared with both unsorted vehicle-treated BMDC and NECA-treated CD86^high cells. NECA-treated CD86^low cells expressed 2.9 ± 0.4 more IL-10 mRNA than did comparably treated CD86^high cells.

Because the NECA-treated CD86^low and CD86^high populations had unique adenosine receptor and cytokine profiles, we further investigated the two populations by flow cytometry for DC lineage and maturation markers. Compared with each other, or to vehicle control-treated cells, there was no evidence that NECA-treated CD86^low or CD86^high populations differentially expressed CD4, CD8, GR-1, CD11b, or CD103, markers associated with different DC subsets (30, 35) (data not shown). Cell surface maturation markers such as MHC-II, CD40, and CD80 were also compared in the CD86^low and CD86^high BMDC to determine whether these markers co-associate with CD86 expression. Only MHC-II was found to segregate with CD86, as CD86^low cells expressed substantially less MHC-II than did CD86^high or vehicle control cells (data not shown).

We previously demonstrated that NECA treatment of LPS-stimulated BMDC inhibited CD4⁺ T cell activation as measured by IL-2 production (Fig. 1C). Because CD86 costimulation is important for T cell activation, we hypothesized that the CD86^low subset of NECA-treated BMDC was primarily responsible for this effect. Thus, sorted CD86^low and CD86^high BMDC that had been treated with NECA and LPS were compared for capacity to support CD4⁺ T cell activation and proliferation in syngeneic and allogeneic co-culture experiments. As shown in Fig. 7, both IL-2 production and T cell proliferation were impaired in cocultures with the CD86^low BMDC, as compared with the CD86^high BMDC or compared with unsorted control BMDC.

FIGURE 7

The CD86^low subset of NECA-treated, LPS-stimulated BMDC have impaired immunogenicity. A, MLR with BMDC derived from C57BL/6 mice and CD4⁺ T cells from BALB/c mice. Sorted CD86^low and CD86^high NECA-treated BMDC and unsorted control BMDC were irradiated (more ...)

Discussion

Adenosine is an important regulator of inflammatory and immune responses, and recent studies have clearly shown that this includes regulation of T cell responses (11, 12, 16, 17). Genetic ablation or pharmacologic blockade of A_2AAR or A_2BAR leads to overexuberant immune responses and pathology (4, 7, 36). Conversely, adenosine analogs are protective in many models of inflammatory disease (11–15). While the direct effects of adenosine on T cells have been studied in some detail, substantially less is known about the indirect effects that occur due to the effects of adenosine on the function of DC. The present study demonstrates that A_2BAR modulates murine BMDC maturation such that their immunogenicity is altered.

Although previous efforts have been made to examine adenosine receptor expression and function on DC, these studies have proved incomplete, and in some cases conflicting. Panther et al. reported that adenosine impairs TNF-α and IL-12 responses to LPS in human monocyte-derived DC, while enhancing IL-10 production (26). However, adenosine did not affect LPS-induced CD86 or MHC-II expression, nor did adenosine treatment impair their capacity to promote CD4⁺ T cell proliferation in an MLR. The authors suggest that the observed responses were mediated via the A_2AAR, whereas A_2BAR was not even expressed (25). In contrast, Hofer et al. reported that adenosine slows the migration of human monocyte-derived DC, but has no effect on cytokine production or surface marker expression in cells stimulated with a cocktail of TNF-α, IL-1β, IL-6, and prostaglandin E₂ (27). A_2BAR mRNA was detected in their cells, but at very low levels compared with A_2AAR or A₃AR. Differences in the stimuli used to mature the DC and/or in the protocols used to harvest and generate the DC may explain the conflicting results.

To investigate the role of adenosine receptors in regulating murine DC, we elected to study BMDC. These cells can be generated in large numbers by in vitro culture and are widely used as a model myeloid DC (37). We found that the nonselective adenosine analog NECA had little measurable effect on TNF-α, IL-12, IL-10, CD86, or MHC-II responses on resting, nonstimulated BMDC. However, in the context of an LPS stimulus, NECA significantly modulated these markers. Our data indicate that IL-10, but not TGFβ, is an important mediator in the regulation of IL-12 and CD86 responses by NECA. Interestingly, TNF-α does not seem to be under the control of IL-10 in this system, suggesting that adenosine differentially regulates these responses. Our combined approach of using adenosine receptor knockout mice and pharmacologic inhibitors strongly suggests that A_2BAR is the predominant immunoregulatory receptor in BMDC. This observation is consistent with the report by Yang et al. indicating a prominent regulatory role for A_2BAR in another APC, the peritoneal macrophage (7). This finding is also consistent with two recent reports demonstrating that A_2BAR modulates DC development and function (38, 39). However, the A_2BAR finding does conflict with a previous study with DC. For instance, Desrosiers et al. concluded that adenosine regulates BMDC cytokine and CD86 expression via A₁AR (29). Although we did not directly address A₁AR in our studies with A₁AR^−/− mice or selective antagonists to the A₁AR, A₁AR mRNA was not detectable in our BMDC, and moreover the observed effects of NECA seem to be entirely accounted for by the combined effects of A_2AAR and A_2BAR. One explanation for this discrepancy may be in the protocols used to generate or manipulate BMDC. For instance, our BMDC were cultivated with 20 ng/ml GM-CSF, in contrast to 3 ng/ml GM-CSF and 3 ng/ml IL-4 in the previous report. To address this we directly compared adenosine receptor expression in BMDC generated with both GM-CSF and IL-4 to our typical BMDC preparation. A_2BAR expression was found to be similar in both BMDC preparations, and the receptor continued to have a substantial functional role. However, it was interesting that both the expression and function of A_2AAR was enhanced in BMDC cultivated with GM-CSF and IL-4. Thus, while the data presented herein show that A_2BAR was predominantly responsible for immunoregulatory effects in the BMDC population we studied, we cannot exclude a role for other adenosine receptors in regulating DC prepared by other means or isolated from distinct tissues. Accordingly, while preliminary studies indicate that DC enriched from intestinal lamina propria express A_2BAR, it will be important in future studies to examine the functional role of A_2BAR in this DC population.

The data reported herein also suggest that BMDC are a heterogeneous population with varying capacity to respond to NECA. CD86 expression was clearly impaired in a subset of BMDC that were stimulated with LPS in the presence of NECA, but some BMDC still expressed elevated CD86. This heterogeneity may reflect the presence of unique DC subsets, or alternatively may indicate that BMDC are at different maturation stages before being treated with NECA. Although it is not evident why two different populations emerge, it is clear that the NECA-responsive CD86^low population expresses a unique adenosine receptor and cytokine expression “signature” and has reduced capacity to stimulate CD4⁺ T cells, as compared with the comparably treated CD86^high cells. The NECA responsive CD86^low population, characterized as IL-12p40^low, IL-10⁺, CD86^low, MHC-II^low, and with poor capacity to stimulate CD4⁺ T cells, has features descriptive of a tolerogenic DC (40, 41). It is not clear whether enhanced A_2BAR expression facilitates NECA impairment of CD86 in a subset of cells and/or whether A_2BAR is elevated as a result of NECA treatment. It also remains to be seen whether NECA confers a unique phenotype on stimulated BMDC, or whether NECA treatment selects for a preexisting population of BMDC with reduced immunogenicity. Another outstanding question is whether NECA responsive CD86^low BMDC favor regulatory T cells and thus active suppression, or whether deficient costimulation leads to anergic CD4⁺ T cells. Future studies will characterize the role that adenosine receptors play in regulating other DC populations and determine whether adenosine favors tolerance in vivo through action on DC. Illumination of adenosine’s role in controlling host responses will have implications for the therapeutic use of adenosine agonists and antagonists to treat inflammatory disorders.

Acknowledgments

We thank Joanne Lannigan, Mike Solga, and Paul Brewer for technical assistance.

Footnotes

¹This work was supported by the Crohn’s and Colitis Foundation of America (CCFA); by National Institutes of Health Grants DK50980, AI069880, AI070491 (to P.B.E.), and AI075526 (to Richard Guerrant for ATL compound development); and by the Immunology and Cell Isolation Core as well as the Molecular Biology Core of the University of Virginia Digestive Health Research Center (DK67629).

³Abbreviations used in this paper: AR, adenosine receptor; ATL692, 1,3-dialkyl-8-hetero substituted xanthine; DC, dendritic cell; NECA, 5′-N-ethylcarboxamidoadenosine; SCH58261, 2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; ZM241385, 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-α][1,3,5] triazin-5-ylamino]ethyl)phenol.

⁴The online version of this article contains supplemental material.

Disclosures

Drs. R. Figler, J. Linden, and J. Rieger own shares in Adenosine Therapeutics.

References

1. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33–39. [PubMed]

2. Murphree LJ, Sullivan GW, Marshall MA, Linden J. Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NFκB in A_2A adenosine receptor induction. Biochem J. 2005;391:575–580. [PubMed]

3. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A_2A receptors. Annu Rev Immunol. 2004;22:657–682. [PubMed]

4. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916–920. [PubMed]

5. Lukashev DE, Smith PT, Caldwell CC, Ohta A, Apasov SG, Sitkovsky MV. Analysis of A_2a receptor-deficient mice reveals no significant compensatory increases in the expression of A_2b, A₁, and A₃ adenosine receptors in lymphoid organs. Biochem Pharmacol. 2003;65:2081–2090. [PubMed]

6. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, Gause WC, Tone M, Pacher P, Vizi ES, Hasko G. Adenosine augments IL-10 production by macrophages through an A_2B receptor-mediated posttranscriptional mechanism. J Immunol. 2005;175:8260–8270. [PMC free article] [PubMed]

7. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, Hilaire CS, Seldin DC, Toselli P, et al. The A_2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006;116:1913–1923. [PMC free article] [PubMed]

8. Mabley J, Soriano F, Pacher P, Hasko G, Marton A, Wallace R, Salzman A, Szabo C. The adenosine A₃ receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol. 2003;466:323–329. [PubMed]

9. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur J Pharmacol. 1998;358:261–268. [PubMed]

10. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5′-nucleotidase (CD73) and A_2B adenosine receptors. Circulation. 2007;115:1581–1590. [PubMed]

11. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting Edge: critical role for adenosine A_2A receptors in the T cell mediated regulation of colitis. J Immunol. 2006;177:2765–2769. [PubMed]

12. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD. A_2A receptor signaling promotes peripheral tolerance by inducing T cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111:251–259. [PubMed]

13. Okusa MD, Linden J, MacDonald T, Huang L. Selective A_2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol. 1999;277:F404–F412. [PubMed]

14. Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Protection from ischemic liver injury by activation of A_2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol. 2004;286:G285–G293. [PubMed]

15. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN, Hasko G. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007;21:2379–2388. [PMC free article] [PubMed]

16. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A_2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203:2639–2648. [PMC free article] [PubMed]

17. Lappas CM, Rieger JM, Linden J. A_2A adenosine receptor induction inhibits IFN-γ production in murine CD4⁺ T cells. J Immunol. 2005;174:1073–1080. [PubMed]

18. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A_2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600–1610. [PubMed]

19. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257–1265. [PMC free article] [PubMed]

20. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine mono-phosphate to adenosine. J Immunol. 2006;177:6780–6786. [PubMed]

21. Borsellino G, Kleinewietfeld M, Di MD, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell’Acqua ML, et al. Expression of ectonucleotidase CD39 by Foxp3⁺ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225–1232. [PubMed]

22. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984–993. [PubMed]

23. Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host-pathogen interface. Nat Immunol. 2006;7:117–120. [PubMed]

24. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–58. [PubMed]

25. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, Norgauer J. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 2001;15:1963–1970. [PubMed]

26. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, Girolomoni G, Norgauer J. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 2003;101:3985–3990. [PubMed]

27. Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, Heufler C. Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J Invest Dermatol. 2003;121:300–307. [PubMed]

28. Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J, Davis ID, Cebon J, Maraskovsky E. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2004;103:1391–1397. [PubMed]

29. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, Mehal WZ, Santamaria P, Shi Y. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol. 2007;179:1884–1892. [PubMed]

30. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol. 2007;8:1086–1094. [PubMed]

31. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol. 2000;165:618–622. [PubMed]

32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(− ΔΔC_T) method. Methods. 2001;25:402–408. [PubMed]

33. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A_2A receptor agonists. Br J Pharmacol. 2001;132:1017–1026. [PubMed]

34. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C. Adenosine inhibits IL-12 and TNF-α production via adenosine A_2a receptor-dependent and independent mechanisms. FASEB J. 2000;14:2065–2074. [PubMed]

35. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7:543–555. [PubMed]

36. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A_2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect. 2003;5:515–526. [PubMed]

37. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77–92. [PubMed]

38. Ben AA, Lefort A, Hua X, Libert F, Communi D, Ledent C, Macours P, Tilley SL, Boeynaems JM, Robaye B. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A_2B receptor. Eur J Immunol. 2008;38:1610–1620. [PubMed]

39. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, Dikov MM. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–1831. [PubMed]

40. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476–483. [PubMed]

41. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435–1440. [PubMed]